136592-20-6

Basic information

• Product Name: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE
• Synonyms: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE;Ethanone, 2-broMo-1-(6-broMo-3-pyridinyl)-;2-BroMo-1-(6-broMopyridin-3-yl)ethanone hydrobroMide
• CAS NO: 136592-20-6
• Molecular Formula: C₇H₅Br₂NO
• Molecular Weight: 278.93
• Mol File: 136592-20-6.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 353.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.943±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.70±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE(136592-20-6)
• EPA Substance Registry System: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE(136592-20-6)

Safety Data

• Hazardous Substances Data: 136592-20-6(Hazardous Substances Data)

Usage

General Description

2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE, also known as 6-Bromo-3-pyridyl methyl ketone, is a chemical compound with the molecular formula C7H6Br2NO. It is a white solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE is a ketone derivative, containing both bromine and pyridine groups, and is often used in organic synthesis and in the production of various organic compounds. Additionally, it has been found to have potential applications in the field of medicinal chemistry, particularly for the development of new drugs and biologically active compounds. 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE is also commonly used as a building block in the preparation of more complex chemical compounds.

Upstream product

• 139042-59-4 1-(6-bromopyridin-3-yl)ethanone 

Downstream Products

• 1254170-77-8 2-bromo-5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]pyridine 
• 1207747-07-6 2-bromo-5-(2-pyridin-2-yl-1,3-oxazole-4-yl)pyridine 

Relevant articles and documents

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer's Disease Affected Brain

In this study, we synthesized of a series of 2-phenyl- and 2-pyridyl-imidazo[1,2-a]pyridine derivatives and examine their suitability as novel probes for single-photon emission computed tomography (SPECT)-based imaging of β-amyloid (Aβ). Among the 11 evaluated compounds, 10 showed moderate affinity to Aβ(1-42) aggregates, exhibiting half-maximal inhibitory concentrations (IC50) of 14.7 ± 6.07-87.6 ± 39.8 nM. In vitro autoradiography indicated that 123I-labeled triazole-substituted derivatives displayed highly selective binding to Aβ plaques in the hippocampal region of Alzheimer's disease (AD)-affected brain. Moreover, biodistribution studies performed on normal rats demonstrated that all 123I-labeled probes featured high initial uptake into the brain followed by a rapid washout and were thus well suited for imaging Aβ plaques, with the highest selectivity observed for a 1H-1,2,3-triazole-substituted 2-pyridyl-imidazopyridine derivative, [123I]ABC577. This compound showed good kinetics in rat brain as well as moderate in vivo stability in rats and is thus a promising SPECT imaging probe for AD in clinical settings.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.